Navigating the potential of algal peptides: health effects, market applications, and scientific challenges.
Algal-derived peptides show potential health benefits, but current evidence from human trials is limited and suggests only modest improvements.
Where it sits
this study against the rest of the glp-1 blends corpusSummary and findings
This review evaluates the health effects and market applications of algal-derived peptides, focusing on their nutritional content and mechanistic actions. Limited human trials suggest modest improvements in various health metrics. The study highlights the need for standardized production and robust clinical evidence.
Abstract
<h4>Introduction</h4>Algae-derived bioactive peptides are gaining recognition as functional ingredients offering health benefits and sustainability advantages over conventional proteins. This review aimed to evaluate the current evidence on algal peptides, focusing on their nutritional content, mechanistic actions, health effects, potential for sustainability, and translational challenges.<h4>Materials and methods</h4>A comprehensive literature search was conducted across PubMed, Scopus, ScienceDirect, Springer, Elsevier, and Google Scholar. Peer-reviewed studies reporting bioactive peptides derived from microalgae, macroalgae, or Cyanophyceae were included. <i>In vitro</i>, animal, and human intervention studies evaluating molecular mechanisms, metabolic outcomes, or clinical relevance were considered.<h4>Results</h4>Available evidence shows that algal peptides exert multifunctional bioactivities, including inhibition of angiotensin-converting enzyme and renin, antioxidant and anti-inflammatory effects, modulation of glucose metabolism <i>via</i> α-amylase, α-glucosidase, and DPP-IV inhibition, and regulation of lipid metabolism and adipogenesis. Frequently studied sources included <i>Limnospira</i>, <i>Chlorella</i>, <i>Auxenochlorella</i>, <i>Nannochloropsis</i>, <i>Undaria</i>, <i>Palmaria</i>, <i>Ulva</i>, and <i>Neopyropia</i>. Limited human trials suggest modest but clinically relevant improvements in blood pressure, glycemic control, lipid profiles, and body-weight-related outcomes, primarily using whole algal biomass or extracts. Life-cycle assessments highlight favorable land-use efficiency and carbon sequestration potential, although economic feasibility is constrained by energy-intensive downstream processing.<h4>Conclusion</h4>Algal-derived peptides demonstrate promising health-promoting effects and align with sustainable nutrition goals. However, their clinical translation is limited by variability in peptide characterization, uncertain bioavailability, and lack of robust human trials. Standardized production methods, improved delivery strategies, comprehensive safety assessments, and well-designed clinical studies are essential to support their application in functional foods and nutraceuticals.